blank
blank

Have your say: EU AI Act consultation on high-risk systems

European Union flag ERDERA

The European Commission has opened a public consultation to gather feedback on the implementation of the AI Act’s rules concerning high-risk AI systems. The aim is to collect practical examples, clarify open questions, and inform upcoming Commission guidelines on the classification of high-risk systems and related obligations.

Under the AI Act, high-risk AI systems fall into two main categories:

  • Important for product safety under the Union’s harmonised legislation on product safety
  • Those that can significantly affect people’s health, safety, or fundamental rights in specific use cases listed in the AI Act.

The consultation also addresses responsibilities across the AI value chain, helping to define roles and accountability for all actors involved.
The Commission invites input from a wide range of stakeholders, including AI developers and providers, businesses and public sector users, academia and research organisations, civil society and citizens, regulatory and supervisory authorities.

The deadline is 18 July 2025. Learn more.

News & Updates

You might also be interested in

Photograph of neurons - CC BY-NC-SA 2.0 by Birth Into Being via Flickr.

NCL Foundation launches €200,000 prize to connect rare and common neurodegeneration research

The NCL Foundation has opened the Rare-to-Common Neurodegeneration Impact Prize, a €200,000 research award supporting collaborative projects that connect CLN3 Batten disease research with more common neurodegenerative or age-related disorder
European Human Genetics Conference - Rotterdam, The Netherlands June 12-15, 2027

European Human Genetics Conference 2027

June 12 - June 15
The conference will take place in Rotterdam on 12–15 June 2027 and is planned as a hybrid event by the European Society of Human Genetics.
uropean Human Genetics Conference (ESHG) 2026

At ESHG 2026 in Gothenburg, ERDERA’s diagnostics work reviewed early progress and the next phase ahead

At the European Human Genetics Conference 2026 in Gothenburg, ERDERA’s Diagnostic Research Workstream reviewed progress, highlighted early results and used a major European genetics meeting to examine how advances in data sharing and genomic analysis may strengthen rare disease diagnosis across countries.
WODC Boston 2026

At World Orphan Drug Congress USA, ERDERA highlights how connected clinical research networks can make rare disease trials more feasible

Boston, 9–11 June 2026: ERDERA's Scientific Coordinator joined the World Orphan Drug Congress USA to set out how stronger clinical research networks can make rare disease trials more feasible across sites and borders.

ERDERA's

search form